Jan Basile to Treatment Outcome
This is a "connection" page, showing publications Jan Basile has written about Treatment Outcome.
Connection Strength
0.308
-
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):162-9.
Score: 0.040
-
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J. 2009 Oct; 102(10 Suppl):S1-S12.
Score: 0.037
-
Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009 Sep; 11(5):371-6.
Score: 0.037
-
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract. 2009 Apr; 63(4):656-66.
Score: 0.035
-
Fixed-dose combination therapy in the treatment of hypertension: ready for prime time. South Med J. 2007 Apr; 100(4):343-4.
Score: 0.031
-
The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich). 2004 Nov; 6(11):621-29; quiz 630-1.
Score: 0.026
-
Aspirin and angiotensin-converting enzyme inhibitors are safe when taken together after acute myocardial infarction in patients with left ventricular dysfunction. J Clin Hypertens (Greenwich). 2001 Nov-Dec; 3(6):376-7.
Score: 0.021
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.014
-
Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies. J Clin Hypertens (Greenwich). 2014 May; 16(5):331-41.
Score: 0.013
-
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. Clin Nephrol. 2013 Oct; 80(4):235-48.
Score: 0.012
-
Highly interactive multi-session programs impact physician behavior on hypertension management: outcomes of a new CME model. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):97-105.
Score: 0.010
-
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008 Oct; 10(10):751-60.
Score: 0.009
-
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008 Sep; 52(3):412-24.
Score: 0.008
-
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008 Jan 28; 168(2):207-17.
Score: 0.008
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
Score: 0.006